EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dysregulated splenic glucocorticoid sensitivity in aging and an a-synuclein transgenic mouse model of Parkinson’s disease

Daniel Rombach, Verena Bopp, Dominik Langgartner, Veselin Grozdanov iD, Jan Kassubek iD, Jaehyun LeeBae, Chadi Touma, Stefan O Reber, Karin M Danzer

Neuroimmunomodulation · 09.11.2026

DOI: 10.1159/nim/adxag016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuroimmunomodulation, online erschienen am 09.11.2026. Verfasst von Daniel Rombach und 8 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Parkinson's disease (PD) and aging both disrupt hypothalamic–pituitary–adrenal (HPA) axis function and peripheral immune homeostasis. Whether aging or α-synuclein (α-syn) pathology alters glucocorticoid (GC) sensitivity of peripheral immune cells has not been investigated.

Methods

Using an ex vivo GC sensitivity assay, we assessed the responsiveness of isolated and lipopolysaccharide (LPS)-stimulated splenocytes to the anti-inflammatory effects of increasing doses of corticosterone (CORT) in a wild-type (WT) aging cohort and in a PD α-syn transgenic mouse model and respective age-matched controls.

Results

Compared with splenocytes from 6-month-old WT mice, splenocytes from 20-month-old WT mice were less sensitive to 0.1 and 0.5 µM CORT. Isolated splenocytes from PD vs. control mice were less sensitive to 0.05, 0.1, and 0.5 µM CORT specifically at 16 months of age, but not at 6 or 20 months of age. As peripheral immune phenotyping revealed neither differences in HPA axis-related parameters nor in splenic GC receptor expression between PD and age-matched control mice, splenic GC resistance in PD mice at 16 months of age seems to be mediated by downstream GR signaling dysfunction.

Conclusion

Together, our results support the hypothesis that α-syn pathology accelerates an aging-associated decline in the peripheral sensitivity to anti-inflammatory GCs and may thereby sustain systemic and neuroinflammatory processes in PD.

Autor:innen und Institutionen

ORCID-Profile: Veselin Grozdanov, Jan Kassubek

Zitieren

APA

Rombach, D., Bopp, V., Langgartner, D., Grozdanov, V., Kassubek, J., LeeBae, J., Touma, C., Reber, S. O., & Danzer, K. M. (2026). Dysregulated splenic glucocorticoid sensitivity in aging and an a-synuclein transgenic mouse model of Parkinson’s disease. Neuroimmunomodulation. https://doi.org/10.1159/nim/adxag016

Vancouver

Rombach D, Bopp V, Langgartner D, Grozdanov V, Kassubek J, LeeBae J, et al. Dysregulated splenic glucocorticoid sensitivity in aging and an a-synuclein transgenic mouse model of Parkinson’s disease. Neuroimmunomodulation. 2026. doi:10.1159/nim/adxag016

BibTeX
@article{Rombach2026,
  author = {Rombach, Daniel and Bopp, Verena and Langgartner, Dominik and Grozdanov, Veselin and Kassubek, Jan and LeeBae, Jaehyun and Touma, Chadi and Reber, Stefan O and Danzer, Karin M},
  title = {Dysregulated splenic glucocorticoid sensitivity in aging and an a-synuclein transgenic mouse model of Parkinson’s disease},
  journal = {Neuroimmunomodulation},
  year = {2026},
  doi = {10.1159/nim/adxag016}
}
Kostenlos starten →